These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21348641)

  • 1. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
    Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
    OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer.
    Götte K; Riedel F; Neubauer J; Schäfer C; Coy JF; Hörmann K
    Int J Oncol; 2001 Aug; 19(2):331-6. PubMed ID: 11445847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations.
    Correa GT; Bernardes VF; de Sousa SF; Diniz MG; Salles JM; Souza RP; De-Paula AM; Gomez RS; Gomes CC
    Tumour Biol; 2015 Nov; 36(11):9059-66. PubMed ID: 26084614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein.
    Leng K; Schlien S; Bosch FX
    J Oral Pathol Med; 2006 Jan; 35(1):19-24. PubMed ID: 16393249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Wichmann G; Rosolowski M; Krohn K; Kreuz M; Boehm A; Reiche A; Scharrer U; Halama D; Bertolini J; Bauer U; Holzinger D; Pawlita M; Hess J; Engel C; Hasenclever D; Scholz M; Ahnert P; Kirsten H; Hemprich A; Wittekind C; Herbarth O; Horn F; Dietz A; Loeffler M;
    Int J Cancer; 2015 Dec; 137(12):2846-57. PubMed ID: 26095926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
    Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
    Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer.
    Beder LB; Gunduz M; Ouchida M; Gunduz E; Sakai A; Fukushima K; Nagatsuka H; Ito S; Honjo N; Nishizaki K; Shimizu K
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):19-27. PubMed ID: 16170569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
    Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
    Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas.
    Gunduz M; Nagatsuka H; Demircan K; Gunduz E; Cengiz B; Ouchida M; Tsujigiwa H; Yamachika E; Fukushima K; Beder L; Hirohata S; Ninomiya Y; Nishizaki K; Shimizu K; Nagai N
    Gene; 2005 Aug; 356():109-17. PubMed ID: 15935570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection.
    Eicheler W; Zips D; Dörfler A; Grénman R; Baumann M
    J Histochem Cytochem; 2002 Feb; 50(2):197-204. PubMed ID: 11799138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
    Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
    N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
    Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
    Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
    Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
    Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer.
    Erber R; Conradt C; Homann N; Enders C; Finckh M; Dietz A; Weidauer H; Bosch FX
    Oncogene; 1998 Apr; 16(13):1671-9. PubMed ID: 9582015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
    Lindenbergh-van der Plas M; Brakenhoff RH; Kuik DJ; Buijze M; Bloemena E; Snijders PJ; Leemans CR; Braakhuis BJ
    Clin Cancer Res; 2011 Jun; 17(11):3733-41. PubMed ID: 21467160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.